Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases
Advertisement
Welichem Biotech Inc. announced that the Australian Patent Office has granted the Company a patent (No.780700) covering compounds in the WBI-1000 series that are useful in the treatment of inflammatory/auto-immune diseases such as psoriasis and inflammatory bowel disease.
A total of 16 claims covering novel compounds, pharmaceutical composition and use were granted with a term lasting to December 2019. This is the first patent issued for the Company's WBI-1000 series of compounds in a cluster of national applications pending in jurisdictions including Australia, Canada, China, Europe, Japan, Korea and the United States.
"This latest patent strengthens the Company's growing proprietary position in pre-targeted therapies that seek to address unmet medical needs in inflammatory/autoimmune diseases," said John Webster, President & CEO of Welichem. "It also provides intellectual property protection for our lead product, WBI-1001, part of a group of pharmaceutical compounds from symbiotic organisms that have great potential to treat a number of diseases and disorders," he added. The Company currently plans to begin formal clinical testing of the drug in early 2006.
Other news from the department research and development
